The price of NeuroSense Therapeutics Ltd (NASDAQ: NRSN) closed at $1.70 in the last session, down -17.48% from day before closing price of $2.06. In other words, the price has decreased by -$0.3600 from its previous closing price. On the day, 916682 shares were traded.
Ratios:
We take a closer look at NRSN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.82 and its Current Ratio is at 1.82.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NRSN now has a Market Capitalization of 23.23M and an Enterprise Value of 20.73M.
Stock Price History:
Over the past 52 weeks, NRSN has reached a high of $2.33, while it has fallen to a 52-week low of $0.40. The 50-Day Moving Average of the stock is 1.5476, while the 200-Day Moving Average is calculated to be 1.0586.
Shares Statistics:
According to the various share statistics, NRSN traded on average about 301.93K shares per day over the past 3-months and 220.16k shares per day over the past 10 days. A total of 13.67M shares are outstanding, with a floating share count of 9.14M. Insiders hold about 33.08% of the company’s shares, while institutions hold 1.04% stake in the company. Shares short for NRSN as of Mar 15, 2024 were 35.08k with a Short Ratio of 0.12, compared to 148.87k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.26% and a Short% of Float of 0.49%.
Earnings Estimates
The company has 1 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.2 for the current quarter, with a high estimate of -$0.2 and a low estimate of -$0.2, while EPS last year was -$0.24. The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.19 and low estimates of -$0.19.
Analysts are recommending an EPS of between -$0.85 and -$0.85 for the fiscal current year, implying an average EPS of -$0.85. EPS for the following year is -$0.8, with 1 analysts recommending between -$0.8 and -$0.8.
